Gene Therapy For Mesothelioma
Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.
1 . A method of treating a human patient diagnosed with mesothelioma, the method comprising: administering celecoxib, pemetrexed, a platin chemotherapeutic and an agent which induces the expression of interferon.
2 . The method of claim 1 , wherein the platin chemotherapeutic comprises cisplatin.
3 . The method of claim 1 , wherein the platin chemotherapeutic comprises carboplatin.
4 . The method of claim 1 , wherein the agent which induces the expression of interferon comprises antigen.
5 . The method of claim 4 , wherein the antigen comprises viral antigen.
6 . The method of claim 5 , where the viral antigen comprises adenovirus antigen.
7 . The method of claim 1 , wherein the agent which induces the expression of interferon comprises a transgene encoding human interferon.
8 . The method of claim 1 , wherein the agent which induces the expression of interferon comprises nadofaragene firadenovec.